This website is for UK Healthcare Professionals only

Superior efficacy in psoriasis vs. ustekinumab2-4

Over 80% of patients achieve PASI 90 with SKYRIZI at 52 weeks.a3

Proportion of patients (NRI) achieving PASI 90 through to Week 52 in UltIMMa-1 and UltIMMA-2.

 

Result from UltIMMa-1 and UltIMMa-2 integrated analysis, two Phase III double-blind randomised, placebo- and active-comparator controlled studies of SKYRIZI in adult patients with moderate to severe plaque psoriasis.
aRanked secondary endpoint.
Co-primary endpoints were proportions of patients achieving PASI 90 and sPGA 0 or 1 at Week 16 with SKYRIZI vs. placebo. Both co-primary endpoints were met (P<0.0001).


At least twice as many patients achieve completely clear skin (PASI 100) with SKYRIZI vs. ustekinumab at 52 weeks.3

Proportion of patients (NRI) achieving PASI 100 through to Week 52 in UltIMMa-1 and UltIMMA-2.

Result from UltIMMa-1 and UltIMMa-2 integrated analysis, two Phase III double-blind randomised, placebo- and active-comparator controlled studies of SKYRIZI in adult patients with moderate to severe plaque psoriasis.
aRanked secondary endpoint.
Co-primary endpoints were proportions of patients achieving PASI 90 and sPGA 0 or 1 at Week 16 with SKYRIZI vs. placebo. Both co-primary endpoints were met (P<0.0001).

More than 80% of SKYRIZI patients maintained PASI 90 through to 2.5 years2

UltIMMa open-label extension PASI 90 (LOCF)2

Adapted from Strober B, et al. 2019

The UltIMMa open-label extension is an ongoing, Phase III, single arm, multi-centre study assessing the long-term safety and efficacy of SKYRIZI, following 52-week completion of UltIMMa-1 and UltIMMa-2. Of the 598 patients randomised to SKYRIZI in UltIMMa-1 and UltIMMa-2, 525 entered UltIMMa open label extension and continued SKYRIZI 150mg every 12 weeks.

More than 60% of SKYRIZI patients maintained PASI 100 through to 2.5 years2

UltlMMa open-label extension PASI 100 (LOCF)2

Adapted from Strober B, et al. 2019

The UltIMMa open-label extension is an ongoing, Phase III, single arm, multi-centre study assessing the long-term safety and efficacy of SKYRIZI, following 52-week completion of UltIMMa-1 and UltIMMa-2. Of the 598 patients randomised to SKYRIZI in UltIMMa-1 and UltIMMa-2, 525 entered UltIMMa open label extension and continued SKYRIZI 150mg every 12 weeks.

Significantly higher rates of PASI 90 and sPGA O or 1 vs. placebo at Week 163,4

Co-primary endpoints: Proportion of patients who achieved PASI 90 response and sPGA of 0 or 1 (clear or almost clear) at Week 16 with SKYRIZI vs. placebo. Both co-primary endpoints were met in both studies (P<0.0001).

Over 70% of patients reach DLQI 0 or 1 at one year with SKYRIZI

Compared with up to 47% with ustekinumaba4

How many of your patients could reach a point where psoriasis no longer affects their quality of life? 

Adapted from Gordon et al. 20188

P<0.0001 vs. ustekinumab

Data from UltlMMa-1 and UltlMMa-2. two Phase III double-blind randomised, placebo- and active-comparator controlled studies of SKYRIZI in adult patients with moderate to severe plaque psoriasis.
DLQI, Dermatology Life Quality Index
aRanked secondary endpoint.
Co-primary endpoints were proportions of patients achieving PASI 90 and sPGA 0 or 1 at Week 16 with SKYRIZI vs. placebo. Both co-primary endpoints were met (P<0.0001).

How many of your patients could reach a point where psoriasis no longer affects their quality of life? 

Adapted from Gordon et al. 20188

P<0.0001 vs. ustekinumab

Data from UltlMMa-1 and UltlMMa-2. two Phase III double-blind randomised, placebo- and active-comparator controlled studies of SKYRIZI in adult patients with moderate to severe plaque psoriasis.
DLQI, Dermatology Life Quality Index
aRanked secondary endpoint.
Co-primary endpoints were proportions of patients achieving PASI 90 and sPGA 0 or 1 at Week 16 with SKYRIZI vs. placebo. Both co-primary endpoints were met (P<0.0001).


SKYRIZI efficacy vs ustekinumab in
psoriasis2-4

SKYRIZI efficacy vs secukinmab in psoriasis5,6

SKYRIZI efficacy vs adalimumab in
psoriasis7

References

  1. SKYRIZI: Summary of Product Characteristics.
  2. Strober B, et al. Poster 1714, presented at the 28th European Academy of Dermatology and Venereology (EADV) Congress, 9-13 October 2019, Madrid, Spain.
  3. Lebwohl MD et al. Integrated analysis of UltIMMa 1&2. Poster presented at ADD March 2019 P8108.
  4. Gordon KB et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018;392: 650-661.
  5. Warren RB et al. Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
  6. Risankizumab versus secukinumab for subjects with moderate to severe plaque psoriasis. ClinicalTrials.gov identifier: NCT03478787. Updated September 20, 2019. Accessed March 2, 2020. https://clinicaltrials.gov/ct2/show/NCT03478787.
  7. Reich K et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 2019; 394: 576-586.

UK-RISN-220214. Date of preparation: July 2022. 


SKYRIZI® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
SKYRIZI® (risankizumab) alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
SKYRIZI is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.
Some patients may not be suitable for SKYRIZI. You are advised to read the Prescribing Information (which can be found on tab above). Please also refer to the SKYRIZI Summary of Product Characteristics for important information including special warnings/precautions for use and summary of adverse reactions.
Study design information can be found on the Study Design page.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com